US$ 23.35
fda semaglutide compounding enforcement november 2025 Judge Upholds Deadline Ending Production of Compounded Ozempic and Wegovy Have patients been harmed by
Description
Again, this is an animal study, so it may not hold true for humans

GLP-1 weight loss treatment is generally appropriate for adults with a BMI of 30 or higher, or 27 or higher with weight-related comorbidities such as type 2 diabetes, hypertension, or cardiovascular disease

Offered as general guidance only

The US Food and Drug Administration (FDA) has not approved Ozempic for children

Note: Always consult a licensed healthcare professional if you are unsure about the appearance or safety of your medication
R., Tavares R., et al
